Monday's Health Winners & Losers
Biotech and pharmaceutical companies opened the week with clinical, legal, financial and structural updates, and stocks moved accordingly in both directions, luring indices to dabble a bit in the red.
The pharmaceutical and human vaccine company also said its xaliproden treatment for Alzheimer's disease didn't demonstrate a statistically significant effect in late-stage studies and thus will be discontinued. But Sanofi expects to file its antidepressant saredutant, which was effective in two late-stage trials, for marketing approval in the U.S. and Europe in 2008. Also, another antidepressant, amibergon, met its target in one of four studies and the company expects to assess its complete efficacy data in the next year.
Sanofi also plans to refile its marketing application for obesity drug Acomplia (Zimulti) in the U.S. pending long-term late-stage trial data expected in 2010. The drug, which is already available in Europe, was rejected by the Food and Drug Administration earlier this year when regulators questioned its psychological side effects. Sanofi shares fell 98 cents, or 2.3%, to $41.70.In a smaller update, Schering-Plough (SGP) said Monday that it initiated two large phase III clinical studies with vicriviroc, for adults with HIV who have only the R5-type virus and who have already tried another treatment.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV